• Best-in-class serological biomarker detecting true fibrogenesis
  • Diagnostic, prognostic and can be pharmacologically modulated
  • High sensitivity and specificity
  • IVD enabled on the automated Roche cobas® e platform
  • Used as an enrollment criteria for both phase 2 and phase 3 clinical trials in MASH

The nordicPRO-C3™ (PRO-C3) biomarker assay is a breakthrough solution for accurate assessment and monitoring of liver fibrosis, offering a potential non-invasive alternative to the invasive liver biopsy.

The PRO-C3 biomarker incorporates all characteristics that make a biomarker stand out: it is diagnostic, prognostic and can be pharmacologically modulated. PRO-C3 with high accuracy to detect MASH, advanced alcohol-related liver fibrosis, and is also used to investigate lung fibrosis, tumor fibrosis (FDA supported), and other major diseases. The diagnostic accuracy of PRO-C3 can be further improved by using the ADAPT algorithm in which the test outperforms currently available non-patented serological fibrosis markers.

PRO-C3 predicts clinical outcomes and disease progression in patients with chronic liver disease, and also enables precise monitoring of treatment response and disease progression over time. Utilizing PRO-C3 as a clinical research biomarker offers a rapid and reliable go-no/go decision tool, enabling efficient evaluation of treatment efficacy and progression in 4-week phase 1b trials for liver-related indications.

Integrated within the FIB-NIT Panel™, PRO-C3 efficiently works with complementary biomarkers such as CTX-III for fibrosis resolution and nordicPRO-C6™ (PRO-C6, Endotrophin) for outcome prediction, offering a comprehensive approach to assessing fibrosis.

A fragment of N-terminal type III collagen.

Therapeutic area
Gastroenterology, Cardiovascular diseases, Cancer, Hepatic diseases, Respiratory diseases, Renal diseases, Dermatology, Rheumatology, Metabolic dysregulation

Biomarker panels
Lung Fibrosis, FIB-NIT Panel™: Fibrosis Non-invasive Tests, Bridging Fibrosis, Liver Fibrosis Outcome, Tissue Fibrosis, Fibrosis / Fibroblasts, Kidney Disease Activity, Kidney Outcome, Kidney Preclinical, Heart Fibrosis, Heart Outcome, Tissue Fibrosis, Mucosal Damage Resolution, Systemic Sclerosis

Fibrogenesis, ECM formation

Alternative names

Please don't hesitate to contact us if you have any questions or other inquiries.

Are you interested in learning more about Nordic Bioscience?
Enter your information in the form and a representative will contact you shortly.

By submitting this form you agree to our terms and conditions.